UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	ROVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	3)														
Name and Address of Reporting Person * Ali-Jackson Kamil				2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD.				3. Date of Earliest Transaction (Month/Day/Year) 05/20/2022							-	Officer (give	e title below)	Otl	er (specify belo	ow)
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)							6. Individual or Joint/Group Filing(Check Applicable Line) X_ Form filed by One Reporting Person Form filed by More than One Reporting Person					
	JTH SAN FRANCISCO, CA 94080 (City) (State) (Zip) Table I-				I - No	Non-Derivative Securities Acq				uired, Disposed of, or Beneficially Owned						
1.Title of S (Instr. 3)				2A. Deemed Execution Date, if r) any		3. Transactio Code (Instr. 8)				ired 5 f (D) C	. Amount of Securities Beneficially Dwned Following Reported Transaction(s)		6. Ownership Form:	7. Nature of Indirect Beneficial		
				(Month	/Day/Yea		ode	V	Amount ((A) or (D)	Price	or India (I)		Direct (D) or Indirect (I) (Instr. 4)	Ownership (Instr. 4)	
Common	Stock		05/20/2022			I	4		8,750	A	\$ 0 1	8,750			D	
Reminder:	Report on a s	separate line for each	n class of securities b	peneficia	lly owned	directly	P	erson n this f	s who res orm are i	not re	quired	collection of	unless the		ned SEC	1474 (9-02)
Reminder:	Report on a s	separate line for each	n class of securities l	Derivat	ive Securi	ties Ac	P ir d	Person n this f lisplay	s who res form are i s a curre	not re ently v	equired to alid OM	to respond IB control n	unless the		ned SEC	1474 (9-02)
1. Title of	2. Conversion	3. Transaction Date (Month/Day/Year)	Table II -	Derivat (e.g., pu 4. Transac Code	ive Securits, calls, v 5. Notion of D Security Acquired or D of (I	ties Accarrant umber crivative rities ired (A sposed)	quired s, opti 6. D Expi (Mo	Person n this f lisplay l, Dispo	s who restorm are as a curre seed of, or nvertible sercisable ar Date	not reently v Benef	equired fralid OM ficially Oties)	owned and Amount rlying	unless the umber.	9. Number Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form of Derivat Security Direct (or Indir (s) (I)	11. Naturo of Indire Benefic Owners: (Instr. 4
1. Title of Derivative Security	2. Conversion or Exercise Price of Derivative	3. Transaction Date	Table II - 3A. Deemed Execution Date, if any	Derivat (e.g., pu 4. Transac Code	ive Securits, calls, v 5. Notion of D Secu Of (I (Inst	ties Accarrant amber erivative rities ired (A sposed)	quired ss, opti 6. D e Expi (Mo	Person n this i lisplay I, Dispo ions, co Pate Exe iration i onth/Day	s who restorm are is a curre assed of, or invertible services and are better than the current of	not reently v Benef	ralid OM ricially O ricially O rices) 7. Title a of Under Securitie	owned and Amount rlying	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Owners Form of Derivat Security Direct (or Indir	11. Nation of Indirection of Section 11. Nation of Indirection of

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Ali-Jackson Kamil RIGEL PHARMACEUTICALS, INC. 1180 VETERANS BLVD. SOUTH SAN FRANCISCO, CA 94080	X					

Signatures

/s/ Dolly Vance (Attorney-in-Fact)	05/23/2022
**Signature of Reporting Person	Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.
- (2) The shares vest monthly over one (1) year from the date of grant subject to the Reporting Person's continuous service on the Company's Board of Directors.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.